Camrelizumab
- Generic Name
- Camrelizumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1798286-48-2
- Unique Ingredient Identifier
- 73096E137E
- Background
Camrelizumab is under investigation in clinical trial NCT03417895 (SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy).
- Indication
⑴用于至少经过二线系统化疗的复发或难治性经典型霍奇金淋巴瘤患者的治疗。
⑵用于霍奇金淋巴瘤（三线）、肝细胞癌（二线）、非鳞状非小细胞肺癌（一线联合）、食管鳞癌（二线）。
⑶用于既往接受过二线及以上化疗后疾病进展或不可耐受的晚期鼻咽癌患者的治疗。
⑷联合顺铂和吉西他滨用于局部复发或转移性鼻咽癌患者的一线治疗。
- Associated Conditions
- -
- Associated Therapies
- -
SHR-1210 in Recurrent/Metastatic Nasopharyngeal Carcinoma Who Have Received Previous At Least Two Lines of Chemotherapy.
- First Posted Date
- 2018-06-15
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 156
- Registration Number
- NCT03558191
- Locations
- 🇨🇳
Cancer Center of Sun-Yat Sen University (CCSYSU), Guangzhou, Guangdong, China
A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Hypofraction Radiotherapy in Patients With NSCLC
- First Posted Date
- 2018-06-15
- Last Posted Date
- 2020-02-05
- Lead Sponsor
- Shandong Cancer Hospital and Institute
- Target Recruit Count
- 42
- Registration Number
- NCT03557411
- Locations
- 🇨🇳
Shandong Cancer Hospital and Institute, Jinan, Shandong, China
Anti-CTLA-4 Antibody Followed by Anti-PD-1 Antibody in Recurrent or Metastatic NSCLC
- First Posted Date
- 2018-05-17
- Last Posted Date
- 2018-05-30
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 10
- Registration Number
- NCT03527251
- Locations
- 🇨🇳
Cancer Center of Sun-Yat Sen University (CCSYSU), GuangZhou, Guangdong, China
PD-1 Antibody Versus Best Supportive Care After Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma
- First Posted Date
- 2018-02-09
- Last Posted Date
- 2024-04-09
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 450
- Registration Number
- NCT03427827
- Locations
- 🇨🇳
Xiangya Hospital Central South University, Changsha, Hunan, China
🇨🇳First People's Hospital of Foshan, Foshan, Guangdong, China
🇨🇳Guangzhou Medical University Cancer Hospital, Guangzhou, Guangdong, China
SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy
- First Posted Date
- 2018-01-31
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 59
- Registration Number
- NCT03417895
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Science, Beijing, Beijing, China
🇨🇳Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
A Trial of SHR-1210 (an Anti-PD-1 Antibody) in Combination With Apatinib in Patients With Advanced TNBC
- First Posted Date
- 2018-01-09
- Last Posted Date
- 2020-10-23
- Target Recruit Count
- 40
- Registration Number
- NCT03394287
- Locations
- 🇨🇳
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China
SHR-1210 in Patients With Relapsed or Refractory Extranodal NK/T Cell Lymphoma
- First Posted Date
- 2017-12-06
- Last Posted Date
- 2020-06-18
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 97
- Registration Number
- NCT03363555
- Locations
- 🇨🇳
First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Apatinib Plus Anti-PD1 Therapy for Advanced Osteosarcoma
- Conditions
- Interventions
- First Posted Date
- 2017-12-02
- Last Posted Date
- 2020-05-19
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 43
- Registration Number
- NCT03359018
- Locations
- 🇨🇳
Musculoskeletal Tumor Center of Peking University People's Hospital, Beijing, China
🇨🇳Peking University Shougang Hospital, Beijing, China
Two Stage Study of Combination of Chemotherapy, SHR-1210 and/or Decitabine for Relapsed/Refractory PMBCLs
- Conditions
- Interventions
- First Posted Date
- 2017-11-17
- Last Posted Date
- 2018-12-03
- Lead Sponsor
- Chinese PLA General Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT03346642
- Locations
- 🇨🇳
Biotherapeutic Department and Pediatrics Department of Chinese PLA General Hospital, Beijing, Beijing, China
🇨🇳Biotherapeutic Department of Chinese PLA General Hospital, Beijing, Beijing, China
SHR-1210 Alone or in Combination With Decitabine in Relapsed or Refractory Hodgkin Lymphoma
- First Posted Date
- 2017-08-16
- Last Posted Date
- 2019-04-01
- Lead Sponsor
- Chinese PLA General Hospital
- Target Recruit Count
- 280
- Registration Number
- NCT03250962
- Locations
- 🇨🇳
Biotherapeutic Department of Chinese PLA General Hospital, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.